Lupin receives USFDA nod for testosterone topical solution

Lupin receives USFDA nod for testosterone topical solution

Lupin logo

 

Lupin announced that it has received the final approval from for its testosterone topical solution from USFDA to market a generic version of Eli Lilly and Company’s Axiron Topical solution.

According to IMS MAT June 2017 data, testosterone topical solution had sales of $244.2 million in the US.

The testosterone topical solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.